Global Intravenous (IV) Iron Drugs Market Report: 2013 Edition- New Report by Koncept Analytics

June 4, 2013 - PRLog -- With the dawn of novel technology era, companies operating in the healthcare/science/pharmaceutical/therapeutic industries are now surmounting the never touched peaks. Also the growth of these industries is overhauled by the unrelenting increase in health related issues emanating from the altering lifestyle and rapidly evolving surrounding environment. Among the respective industries of biological sciences, a booming industry is of IV (Intravenous) iron. Usually oral iron supplements are recommended for restoring and maintaining iron levels in the body, but oral treatment has certain limitations. For the cases where oral supplements are incapable of fulfilling the purpose, IV iron therapy is used as part of which iron is directly injected with a needle into a vein.

This report offers comprehensive analysis of the global iron products market along with the key segments viz. IV Iron and Oral Iron. Herein, the IV iron market is discussed in details. Also, the IV iron replacement therapy market of the US is covered. Furthermore, market dynamics including the key trends and developments, underlying industry growth drivers and the challenges faced by the respective market are analyzed in-depth.On the contention front, the market for IV iron is highly competitive with a handful of players dominating the whole market. The competitive landscape along with the profiles of leading industry players is also included in this report.

This report consists of the following sections:

1. Iron in Human Body: An Overview

1.1 IV Iron Application Areas
1.1.1 IV Iron Application in Nephrology
1.2 Iron Deficiency- Anemia
1.3 IV Iron Therapy for Anemia Treatment

2. Iron Medication Market Structure

2.1 Global Iron Products Market
-Market Value
-Market Segments

2.1.1 Global IV Iron Market
-Market Value

2.2 The US IV Iron Market
-Market Value
-Non-Dialysis IV Iron Market

3. Market Dynamics

3.1 Industry Trends and Developments

3.1.1 New Product Development- Soluble Ferric Pyrophosphate (SFP)
3.1.2 Bundled Payment System

3.2 Growth Drivers

3.2.1 Increasing Use of IV Iron in Gynecology
3.2.2 IV Iron Improves Quality of Treatment outside Dialysis
3.2.3 Increasing Dialysis Patient Population
3.2.4 Growing Number of Diabetic Patients Worldwide
3.2.5 Increasing Cases of Hypertension
3.2.6 Rising Healthcare Expenditure
3.2.7 Higher Spending on Medicines
3.2.8 Growing Ageing Population (+60 Years)
3.2.9 Ameliorating Economic Conditions
3.2.10 Increasing Insurance Density

3.3 Challenges

3.3.1 Stringent Regulation
3.3.2 Concerns Regarding Adverse Effects

4. Competitive Landscape

4.1 US Market
4.2 Product Contention

5. Company Profiles

5.1 Galenica Pharmaceuticals

5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Strong Foothold in Healthcare Market
-Focus on New Product Development

5.2 Actavis Inc.

5.2.1 Business Description
5.2.2 Financial Overview
5.2.3 Business Strategies
-Strategic Acquisitions
-Intense R&D Activities

5.3 AMAG Pharmaceuticals

5.3.1 Business Oveview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on Research & Development
-Expanding the Existing Labels

6. Market Outlook

6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

List of Charts

Global Iron Products Market (2008-2012)
Global Iron Products Market Share (2012)
Global IV Iron Market (2006-2010)
The US IV Iron Market Size (2008-2011)
US Non-Dialysis IV Iron Market (2011 & 2012)
IV Iron – Avoidance of ESA Initiation in Pre Dialysis Patients
IV Iron – Response Rate to ESA with/without IV Iron (2004-2011)
Dialysis Patient Population Worldwide (2005-2015E)
Dialysis Patient Population Share by Region (2011)
Global Diabetes Population (2006-2011)
Causes of ESRD in the US (2011)
Worldwide Patients with End Stage Renal Disease (2005-2011)
Hypertension Prevalence in the US (2010-2015E)
Hypertension Prevalence in the Developed Europe (2010-2015E)
Global Healthcare Spending (2005-2015E)
Global Spending on Medicines (2006-2016E)
Global Spending on Medicine Share by Region (2006-2016E)
The US Spending on Medicine (2007-2016E)
Japan’s Spending on Medicine (2007-2016E)
Global Ageing Population (2005-2013F)
Global GDP (2001-2011)
World GDP per Capita (2005-2011)
Global Insurance Density (2004-2011)
Long and Short Term Concerns about IV Iron
IV Iron Market Share in the US (January 2012)
Galenica’s Revenue Share by Business Segments (2012)
Galenica’s Net Sales and Net profit (2009-2012)
Actavis’ Revenue Share by Business Segment (2012)
Actavis’ Revenues and Net Income (2009-2012)
AMAG Pharmaceuticals’ Revenues (2009-2012)
Global IV Iron Market Forecast (2010-2015E)

List of Tables

Risk Factors for CKD
SFP Clinical Trials
IV Iron Products – Safety Profile
The US Non-Dialysis IV Iron Market (2011 & 2012)
IV Iron Administration Comparison
Dependent & Independent Variables (2006-2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

For further details, kindly visit: http://www.konceptanalytics.com/reportDetail.aspx?reportID=468